Methods for treatment of muscular dystrophy
The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.
1. A method for increasing muscle strength in a subject having muscular dystrophy, the method comprising administering to the subject a therapeutically effective amount of an anti-connective tissue growth factor (CTGF) antibody or fragment thereof, thereby increasing muscle strength.
2. The method of claim 1 , wherein muscular dystrophy is selected from the group consisting of Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
3. The method of claim 1 , wherein the subject is human.
4. The method of claim 1 , wherein the anti-CTGF antibody is a monoclonal antibody or a fragment thereof.
5. The method of claim 4 , wherein the anti-CTGF monoclonal antibody is CLN-1, or a fragment thereof.
6. The method of claim 1 , further comprising administering an angiotensin receptor blocker, a statin, a calcium channel blocker, a beta-blocker, a glucocorticoid, an advanced glycation endproduct inhibitor or a diuretic.
7. A method for increasing the maximal force or tetanus strength of muscle in a subject having muscular dystrophy, the method comprising administering to the subject a therapeutically effective amount of an anti-CTGF antibody or fragment thereof, thereby increasing the maximal force or tetanus strength of muscle.
8. The method of claim 7 , wherein muscular dystrophy is selected from the group consisting of Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
9. The method of claim 7 , wherein the subject is human.
10. The method of claim 7 , wherein the anti-CTGF antibody is a monoclonal antibody or a fragment thereof.
11. The method of claim 10 , wherein the anti-CTGF monoclonal antibody is CLN-1, or a fragment thereof.
12. The method of claim 7 , further comprising administering an angiotensin receptor blocker, a statin, a calcium channel blocker, a beta-blocker, a glucocorticoid, an advanced glycation endproduct inhibitor or a diuretic.